Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540205 | 0.73 | ALDH1A1 (0.48) | ALDH1A1CYP1A2SMN1; SMN2TSHRGRIN2D | |
| SCHEMBL8098659 | 0.73 | ALDH1A1 (0.48) | ALDH1A1CYP1A2SMN1; SMN2TSHRGRIN2D | |
| SCHEMBL611476 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CYP1A2SMN1; SMN2TSHR | |
| SCHEMBL11498930 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CYP1A2SMN1; SMN2TSHR | |
| SCHEMBL822282 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CYP1A2SMN1; SMN2TSHR | |
| SCHEMBL10972334 | 0.73 | ALDH1A1 (0.42) | ALDH1A1CYP1A2SMN1; SMN2TSHRGRIN2D | |
| SCHEMBL3258454 | 0.73 | ALDH1A1 (0.54) | ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL3360577 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL6685776 | 0.71 | ALDH1A1 (0.41) | ALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL22591335 | 0.69 | ALDH1A1 (0.39) | ALDH1A1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059539-B1 | USE OF A GLYOXYLATED VINYLAMIDE POLYMER AS DRY AND WET STRENGTH AID FOR PAPER | BASF SE (DE) | 2011-11-16 | — | — | EP | claimed |
| CN-110268114-B | High molecular weight temporary wet strength resins for paper | 索理思科技开曼公司 | 2022-12-13 | — | — | CN | disclosed |
| CN-113785029-A | Compositions and methods for increasing wet and dry paper strength | 索理思科技开曼公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3130615-B1 | GLYOXALATION OF VINYLAMIDE POLYMER | SOLENIS TECHNOLOGIES CAYMAN LP (KY) | 2021-03-10 | — | — | EP | disclosed |
| US-9962369-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9949952-B2 | Methods and compositions for transdermal delivery | SPRAYABLE HOLDINGS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3130615-A1 | GLYOXALATION OF VINYLAMIDE POLYMER | BASF SE (DE) | 2017-02-15 | — | — | EP | disclosed |
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | SPRAYABLE HOLDINGS, INC. | 2016-11-03 | — | — | US | disclosed |
| EP-2386579-B1 | GLYOXALATION OF VINYLAMIDE POLYMER | BASF SE (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2386580-B1 | GLYOXALATION OF VINYLAMIDE POLYMER | BASF SE (DE) | 2016-10-12 | — | — | EP | disclosed |
| EP-2059539-B1 | USE OF A GLYOXYLATED VINYLAMIDE POLYMER AS DRY AND WET STRENGTH AID FOR PAPER | BASF SE (DE) | 2011-11-16 | — | — | EP | disclosed |
| EP-2386580-A2 | Glyoxalation of vinylamide polymer | BASF SE (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-8039031-B2 | Tuning the electromagnetic field relating to a sample parameter and monitoring a sample quality; particularly relating to drying of corn with high energy efficiency to produce high quality dried corn, with a low to very low level of cracks. | Energy Systems Engineering LLC (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110224374-A1 | GLYOXALATED N-VINYLAMINE | BASF SE (DE) | 2011-09-15 | — | — | US | disclosed |
| EP-2343324-A1 | Glyoxalated poly(n-vinylamine) | BASF SE (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2215130-A2 | GLYOXALATED N-VINYLAMINE | BASF SE (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-2059539-A2 | GLYOXALATION OF VINYLAMIDE POLYMER | Ciba Holding Inc. (CH) | 2009-05-20 | — | — | EP | disclosed |
| WO-2009059725-A2 | GLYOXALATED POLY (N-VINYLAMINE) | BASF SE (DE) | 2009-05-14 | — | — | WO | disclosed |
| WO-2008028865-A2 | GLYOXALATION OF VINYLAMIDE POLYMER | CIBA HOLDING INC. (GB) | 2008-03-13 | — | — | WO | disclosed |
| US-4221617-A | HETEROPOLYMERS, ALKYLARYL SULFONATES | UNITED TECHNOLOGIES CORPORATION (US) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317435-A1 | METHODS AND COMPOSITIONS FOR TRANSDERMAL DELIVERY OF CAFFEINE IN THE FORM OF SOLUTIONS OR SUSPENSIONS | TES, CCR7, CES2 | ALDH1A1 1876/4885CYP1A2 35/4885SMN1; SMN2 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.